Los Angeles, CA, May 21, 2019 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) and Veterans Healthcare Supply Solutions Inc. (VHSS) today announced a long-term agreement encompassing the distribution of SofPulse® to Veterans Administration Facilities and Department of Defense Healthcare Facilities.
Alan Collier, Endonovo’s Chief Executive Officer, stated, “The team at VHSS have streamlined and improved the sales, marketing and distribution of medical devices to VA and DoD facilities. VHSS is a true leader in the space and we are thrilled to have the capacity to support their mission. This agreement, which includes direct delivery to all medical facilities, extends beyond traditional distribution and includes access to their 900 Federal Contract Officers as well as their distribution center with a state of the art ERP and WMS Systems.”
Gary Skura, President VHSS - VHSS is excited to partner with Endonovo, as our primary goal is providing leading edge products and services to eligible federal government healthcare constituents. Our new partnership with Endonovo will certainly allow us to further continue our core objectives.
About Veterans Healthcare Supply Solutions Inc.
Founded in 2010 and headquartered in Jacksonville, Florida, USA, VHSS is a diversified medical equipment and healthcare supplies distributor focusing primarily on the federal healthcare market. VHSS was founded by Gary Skura, a retired Navy pilot with over 30 years of healthcare distribution experience. VHSS represents many large manufacturers covering a wide range of products in nearly every major category in healthcare. VHSS was recognized as a Top Service-Disabled Veteran Owned Small Business (SDVOSB) for 2014 and 2015 by U.S. Veterans Magazine, won the Best Veterans Healthcare Products Supplier for 2016 by The Small Cap Awards, and was selected as the Best of Jacksonville for Medical Equipment Distribution for 2016, 2017, 2018 and 2019. VHSS was inducted into the Jacksonville Small Business Hall of Fame in 2017.
About Endonovo Therapeutics
Endonovo Therapeutics, Inc. is a commercial-stage developer of non-invasive wearable Electroceuticals™ therapeutic devices. The Company's current portfolio of commercial and clinical-stage wearable Electroceuticals™ therapeutic devices addresses wound healing, pain, post-surgical pain and edema, cardiovascular disease, chronic kidney disease, and Central Nervous System (CNS) Disorders, including traumatic brain injury (TBI), acute concussions, post- concussion syndrome and multiple sclerosis. The Company's non-invasive Electroceutical™ therapeutic device, SofPulse®, using pulsed short-wave radiofrequency at 27.12 MHz has been FDA-Cleared and CE Marked for the palliative treatment of soft tissue injuries and post-operative pain and edema, and has CMS National Coverage for the treatment of chronic wounds. The Company's current portfolio of pre-clinical stage Electroceuticals™ therapeutic devices address chronic kidney disease, liver disease non-alcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The Company's non-invasive, wearable Electroceuticals™ therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth factor cascades necessary for healing to occur. www.endonovo.com
Safe Harbor Statement
This press release contains information that constitutes forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, trends, analysis, and other information contained in this press release including words such as "anticipate," "believe," "plan," "estimate," "expect," "intend," and other similar expressions of opinion, constitute forward-looking statements. Any such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any future results described within the forward-looking statements. Risk factors that could contribute to such differences include those matters more fully disclosed in the Company's reports filed with the Securities and Exchange Commission. The forward-looking information provided herein represents the Company's estimates as of the date of the press release, and subsequent events and developments may cause the Company's estimates to change. The Company specifically disclaims any obligation to update the forward-looking information in the future. Therefore, this forward-looking information should not be relied upon as representing the Company's estimates of its future financial performance as of any date subsequent to the date of this press release.
Investor Relations Contact:
Endonovo Therapeutics, Inc.
Mr. Andrew Barwicki
516-662-9461
Andrew@barwicki.com
www.endonovo.com